HRTX · Heron Therapeutics, Inc. /De/
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. Heron reported Q2 net revenue of $37.7 million with strong acute care growth (ZYNRELEF +35% and APONVIE +74% year-over-year), but withdrew its full-year 2026 guidance following a June court decision on CINVANTI patents that threatens potential generic entry. The company reset its Hercules credit facility, reducing principal by up to $17.5 million and resetting covenants through 2027, and is evaluating strategic alternatives.
- + Acute care franchise delivered $15.3 million, up 43.9% year-over-year
- + ZYNRELEF net revenue grew 35% year-over-year to $11.1 million
- + APONVIE net revenue grew 74% year-over-year to $4.2 million with 23% NK1 segment share
- + Hercules credit facility amended with covenants reset through 2027 and up to $17.5 million principal reduction
- + Adjusted EBITDA improved to $3.2 million from $2.2 million year-over-year
- − Withdrew full-year 2026 guidance of $173-183 million net product sales and $10-20 million adjusted EBITDA
- − CINVANTI declined 9.7% year-over-year to $21.8 million due to branded competition and faces potential generic entry
- − ZYNRELEF Q2 performance came in below company expectations
- − Net loss widened to $5.5 million from $2.4 million year-over-year
- − Pro forma cash falls to approximately $24.3 million after September payment from $42.7 million
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HRTX
this stock
Heron Therapeutics, Inc. /De/
|
$65.29M | -73.5% | +7.4% | — | 24.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$141.42B | +20.5% | +46.2% | 32.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.84B | +7.2% | +20.8% | 20.9 | 2.3% |
|
ARGX
Argenx SE
|
$64.44B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Amount
- $1.0K–$15.0K
- Traded
- Mar 31, 2021
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HRTX | +5.3% | -29.8% | -61.8% | +8.1% | -73.6% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +5.2% | -29.4% | -76.9% | +7.7% | -86.5% |